Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 6.98
NAS:PACB's Cash-to-Debt is ranked higher than
54% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NAS:PACB: 6.98 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PACB' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.47  Med: 7.18 Max: No Debt
Current: 6.98
4.47
No Debt
Equity-to-Asset 0.67
NAS:PACB's Equity-to-Asset is ranked lower than
52% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NAS:PACB: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PACB' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.75  Med: 0.6 Max: 0.92
Current: 0.67
-1.75
0.92
Debt-to-Equity 0.13
NAS:PACB's Debt-to-Equity is ranked higher than
67% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. NAS:PACB: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:PACB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01  Med: 0.14 Max: 0.26
Current: 0.13
-0.01
0.26
Debt-to-EBITDA -0.16
NAS:PACB's Debt-to-EBITDA is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. NAS:PACB: -0.16 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:PACB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.6  Med: -0.17 Max: -0.02
Current: -0.16
-0.6
-0.02
Piotroski F-Score: 2
Altman Z-Score: 3.04
Beneish M-Score: -3.82
WACC vs ROIC
8.44%
-301.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -128.44
NAS:PACB's Operating Margin % is ranked lower than
72% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NAS:PACB: -128.44 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PACB' s Operating Margin % Range Over the Past 10 Years
Min: -65237.04  Med: -201.8 Max: -31.4
Current: -128.44
-65237.04
-31.4
Net Margin % -130.44
NAS:PACB's Net Margin % is ranked lower than
73% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NAS:PACB: -130.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:PACB' s Net Margin % Range Over the Past 10 Years
Min: -64965.19  Med: -205.91 Max: -34.16
Current: -130.44
-64965.19
-34.16
ROE % -98.57
NAS:PACB's ROE % is ranked lower than
83% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NAS:PACB: -98.57 )
Ranked among companies with meaningful ROE % only.
NAS:PACB' s ROE % Range Over the Past 10 Years
Min: -272.85  Med: -94.02 Max: -46.42
Current: -98.57
-272.85
-46.42
ROA % -64.81
NAS:PACB's ROA % is ranked lower than
77% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NAS:PACB: -64.81 )
Ranked among companies with meaningful ROA % only.
NAS:PACB' s ROA % Range Over the Past 10 Years
Min: -81.89  Med: -57.48 Max: -24.8
Current: -64.81
-81.89
-24.8
ROC (Joel Greenblatt) % -227.13
NAS:PACB's ROC (Joel Greenblatt) % is ranked lower than
69% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NAS:PACB: -227.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PACB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1441.77  Med: -632.19 Max: -227.13
Current: -227.13
-1441.77
-227.13
3-Year Revenue Growth Rate -22.00
NAS:PACB's 3-Year Revenue Growth Rate is ranked lower than
63% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:PACB: -22.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:PACB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22  Med: 15.8 Max: 38.8
Current: -22
-22
38.8
3-Year EBITDA Growth Rate -27.50
NAS:PACB's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:PACB: -27.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:PACB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.5  Med: 32.25 Max: 78.8
Current: -27.5
-27.5
78.8
3-Year EPS without NRI Growth Rate -21.90
NAS:PACB's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:PACB: -21.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:PACB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.8 Max: 78.6
Current: -21.9
0
78.6
GuruFocus has detected 5 Warning Signs with Pacific Biosciences of California Inc NAS:PACB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PACB's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

PACB Guru Trades in Q1 2018

Steven Cohen 2,100,000 sh (New)
Lee Ainslie 12,173,094 sh (+8.46%)
Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q2 2018

PACB Guru Trades in Q2 2018

Steven Cohen 2,900,000 sh (+38.10%)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 12,173,094 sh (unchged)
» More
Q3 2018

PACB Guru Trades in Q3 2018

Louis Moore Bacon 125,000 sh (New)
Steven Cohen 5,175,000 sh (+78.45%)
Lee Ainslie 12,173,094 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
Q4 2018

PACB Guru Trades in Q4 2018

Mario Gabelli 329,450 sh (New)
Jeremy Grantham 31,900 sh (New)
Prem Watsa 160,000 sh (New)
George Soros 135,000 sh (New)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:XKRX:180400, NAS:OXFD, ROCO:4103, XKRX:038290, OSTO:IMMNOV, NYSE:NVTA, NYSE:ENZ, XKRX:086040, NAS:CDNA, TSE:4595, MEX:MEDICA B, TSE:2309, AMEX:SENS, ASX:IDX, NAS:SRDX, AMEX:PTN, NAS:FLDM, NAS:TTOO, ISX:PRDA, OSTO:CEVI » details
Traded in other countries:P09.Germany,
Headquarter Location:USA
Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development, and manufacture of sequencing system to help scientists resolve genetically complex problems.

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Top Ranked Articles about Pacific Biosciences of California Inc

Latest PacBio Sequencing Advancements Including Preview of Sequel II System to be Featured at Annual AGBT Conference
Pacific Biosciences Announces Fourth Quarter and Annual 2018 Financial Results
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Pacific Biosciences of California, Inc. (PACB) on Behalf of Stockholders and Encourages PACB Investors to Contact the Firm
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Pacific Biosciences of California, Inc. - PACB
PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito
Consolidated Research: 2018 Summary Expectations for Pacific Biosciences of California, NXP Semiconductors N.V., Consolidated Communications, Alexander & Baldwin, Willdan Group, and OneMain — Fundamental Analysis, Key Performance Indications
Pacific Biosciences of California, Inc. Third Quarter 2018 Financial Results Call
PacBio Long-Read Sequencing Featured at ASHG Annual Meeting
Pacific Biosciences Announces a New Paradigm in DNA Sequencing – Highly Accurate Single-Molecule Long Reads
Pacific Biosciences Releases Highest-Quality, Most Contiguous Individual Human Genome Assembly to Date

Ratios

vs
industry
vs
history
PB Ratio 9.62
PACB's PB Ratio is ranked higher than
54% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. PACB: 9.62 )
Ranked among companies with meaningful PB Ratio only.
PACB' s PB Ratio Range Over the Past 10 Years
Min: 0.52  Med: 4.48 Max: 19.08
Current: 9.62
0.52
19.08
PS Ratio 12.59
PACB's PS Ratio is ranked higher than
57% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. PACB: 12.59 )
Ranked among companies with meaningful PS Ratio only.
PACB' s PS Ratio Range Over the Past 10 Years
Min: 2  Med: 6.85 Max: 28.58
Current: 12.59
2
28.58
EV-to-EBIT -10.23
PACB's EV-to-EBIT is ranked lower than
99.99% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. PACB: -10.23 )
Ranked among companies with meaningful EV-to-EBIT only.
PACB' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.7  Med: -3.9 Max: 0.5
Current: -10.23
-33.7
0.5
EV-to-EBITDA -11.02
PACB's EV-to-EBITDA is ranked lower than
99.99% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. PACB: -11.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
PACB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.7  Med: -4.1 Max: 0.6
Current: -11.02
-38.7
0.6
EV-to-Revenue 13.02
PACB's EV-to-Revenue is ranked higher than
60% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. PACB: 13.02 )
Ranked among companies with meaningful EV-to-Revenue only.
PACB' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.7  Med: 5.5 Max: 378.4
Current: 13.02
-2.7
378.4
Current Ratio 4.90
PACB's Current Ratio is ranked higher than
64% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. PACB: 4.90 )
Ranked among companies with meaningful Current Ratio only.
PACB' s Current Ratio Range Over the Past 10 Years
Min: 2.9  Med: 5.61 Max: 22.74
Current: 4.9
2.9
22.74
Quick Ratio 4.23
PACB's Quick Ratio is ranked higher than
59% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PACB: 4.23 )
Ranked among companies with meaningful Quick Ratio only.
PACB' s Quick Ratio Range Over the Past 10 Years
Min: 2.61  Med: 5.16 Max: 22.74
Current: 4.23
2.61
22.74
Days Inventory 150.02
PACB's Days Inventory is ranked lower than
63% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. PACB: 150.02 )
Ranked among companies with meaningful Days Inventory only.
PACB' s Days Inventory Range Over the Past 10 Years
Min: 103.43  Med: 129.84 Max: 196.1
Current: 150.02
103.43
196.1
Days Sales Outstanding 39.90
PACB's Days Sales Outstanding is ranked higher than
66% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. PACB: 39.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
PACB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.52  Med: 39.9 Max: 74.35
Current: 39.9
20.52
74.35
Days Payable 45.93
PACB's Days Payable is ranked lower than
56% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. PACB: 45.93 )
Ranked among companies with meaningful Days Payable only.
PACB' s Days Payable Range Over the Past 10 Years
Min: 28.8  Med: 50.49 Max: 83.1
Current: 45.93
28.8
83.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.10
PACB's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. PACB: -23.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PACB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -380.3  Med: -14.4 Max: -7.8
Current: -23.1
-380.3
-7.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 23.74
PACB's Price-to-Net-Cash is ranked lower than
88% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. PACB: 23.74 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PACB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.02  Med: 18.23 Max: 66
Current: 23.74
1.02
66
Price-to-Net-Current-Asset-Value 14.43
PACB's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. PACB: 14.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PACB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.89  Med: 6.33 Max: 19.89
Current: 14.43
0.89
19.89
Price-to-Tangible-Book 9.68
PACB's Price-to-Tangible-Book is ranked higher than
70% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. PACB: 9.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PACB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.8  Med: 4.16 Max: 14.29
Current: 9.68
0.8
14.29
Price-to-Median-PS-Value 1.84
PACB's Price-to-Median-PS-Value is ranked higher than
87% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PACB: 1.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PACB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.11 Max: 1.85
Current: 1.84
0.43
1.85
Earnings Yield (Greenblatt) % -9.79
PACB's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. PACB: -9.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PACB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3441.4  Med: -20 Max: 26741.7
Current: -9.79
-3441.4
26741.7

More Statistics

Revenue (TTM) (Mil) $78.63
EPS (TTM) $ -0.77
Beta0.95
Volatility92.81%
52-Week Range $2.02 - 7.84
Shares Outstanding (Mil)150.96

Analyst Estimate

Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.52
EPS without NRI ($) -0.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}